We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+23.73%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$8.79B
AUM Growth
-$8.56B
Cap. Flow
-$9.86B
Cap. Flow %
-112.21%
Top 10 Hldgs %
80.97%
Holding
105
New
4
Increased
25
Reduced
11
Closed
21

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$152M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.3M
3
RVMD icon
Revolution Medicines
RVMD
+$59M
4
REPL icon
Replimune Group
REPL
+$57.6M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$46M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$9.45B
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$337M
3
ONC
BeOne Medicines Ltd
ONC
+$199M
4
SWTX
SpringWorks Therapeutics
SWTX
+$69.4M
5
ROIV icon
Roivant Sciences
ROIV
+$41.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.37%
2 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SANA icon
51
Sana Biotechnology
SANA
$852M
$8.16M 0.09%
2,000,000
– –
SGMT icon
52
Sagimet Biosciences
SGMT
$435M
$7.89M 0.09%
1,456,518
+641,159
+79% +$3.02M
CELC icon
53
Celcuity
CELC
$3.96B
$7.8M 0.09%
535,478
– –
LONA
54
LeonaBio Inc
LONA
$66.4M
$7.66M 0.09%
315,381
– –
OPT
55
DELISTED
Opthea Limited American Depositary Shares
OPT
$7.64M 0.09%
2,588,645
-102,246
-4% -$213K
TNGX icon
56
Tango Therapeutics
TNGX
$4.16B
$7.42M 0.08%
750,000
– –
TSHA icon
57
Taysha Gene Therapies
TSHA
$1.58B
$7.09M 0.08%
4,004,756
+1,500,000
+60% +$2.99M
HOOK
58
DELISTED
HOOKIPA Pharma
HOOK
$6.58M 0.07%
812,815
+6,275
+0.8% +$34.6K
MIRM icon
59
Mirum Pharmaceuticals
MIRM
$6.58B
$5.62M 0.06%
190,476
– –
XNCR icon
60
Xencor
XNCR
$1.45B
$5.21M 0.06%
245,431
+122,304
+99% +$2.33M
CYPH
61
Cypherpunk Technologies Inc
CYPH
$63.1M
$4.86M 0.06%
1,172,175
– –
DSGN icon
62
Design Therapeutics
DSGN
$743M
$3.98M 0.05%
1,500,000
– –
TLIS
63
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$3.79M 0.04%
508,323
– –
CATX icon
64
Perspective Therapeutics
CATX
$318M
$3.07M 0.03%
763,970
– –
PCVX icon
65
Vaxcyte
PCVX
$7.62B
$3.07M 0.03%
48,885
– –
PRAX icon
66
Praxis Precision Medicines
PRAX
$8.14B
$2.93M 0.03%
131,533
+6,205
+5% +$112K
IPSC icon
67
Century Therapeutics
IPSC
$364M
$2.65M 0.03%
797,460
-351,880
-31% -$641K
MRSN
68
DELISTED
Mersana Therapeutics
MRSN
$2.52M 0.03%
43,445
– –
CMPX icon
69
Compass Therapeutics
CMPX
$351M
$2.43M 0.03%
1,557,630
– –
ACHL
70
DELISTED
Achilles Therapeutics
ACHL
$1.87M 0.02%
2,102,792
-454,357
-18% -$390K
KALA icon
71
KALA BIO
KALA
$11.7M
$1.87M 0.02%
5,332
– –
ALGS icon
72
Aligos Therapeutics
ALGS
$25.9M
$1.38M 0.02%
83,056
– –
NVTA
73
DELISTED
Invitae Corporation
NVTA
$1.11M 0.01%
1,764,546
– –
PFE icon
74
Pfizer
PFE
$144B
$1.01M 0.01%
+35,000
New +$1.06M
PMVP icon
75
PMV Pharmaceuticals
PMVP
$57.6M
$998K 0.01%
322,024
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Baker Bros. Advisors held 105 positions worth $8.79B, down 49% from $17.4B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Baker Bros. Advisors withdrew a net $9.86B in Q4 2023, closing 21 positions and reducing 11 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $9.45B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Cerevel Therapeutics Holdings, Inc. Common Stock worth $67.8M.

  • Baker Bros. Advisors's largest Q4 2023 buy was Cerevel Therapeutics Holdings, Inc. Common Stock: 1,600,000 shares worth $67.8M.
  • Baker Bros. Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q4 2023, an estimated $152M increase.
  • Baker Bros. Advisors's biggest Q4 2023 reduction was BeOne Medicines Ltd, cutting an estimated $199M.
  • Baker Bros. Advisors fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $9.45B.
  • Baker Bros. Advisors's ten largest holdings make up 81% of its $8.79B portfolio in Q4 2023.
  • Baker Bros. Advisors opened 4 new positions and closed 21 in Q4 2023.
  • Baker Bros. Advisors's portfolio value fell 49% quarter-over-quarter to $8.79B.

Based on Baker Bros. Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.